A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

NCT05875649 · tracked via the Priya Life Science China tracker

Sponsor

Nanfang Hospital, Southern Medical University

Phase

Observational

Started

2023-07-02

Last updated

2023-07-05

Condition(s) studied

AML

Investigational drug(s) / intervention(s)

CLAG

CLAG: Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure

Study summary

Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.

Eligibility

Sex

ALL

Min age

14 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Acute myeloid leukemia patients with first-induction failure Exclusion Criteria: * Acute myeloid leukemia patients with serious infection and organ dysfunction.

Primary outcome measure(s)

Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure — 6 months
CLAG Regimen improves CR rate in acute myeloid leukemia patients with first-induction failure

Trial sites (2)

Facility	City	Region	Status
Nanfang Hospital of Southern Medical University	Guanzhou	Guangdong
Nanfang Hospital of Southern Medical University	Guanzhou	Guangdong

More Nanfang Hospital, Southern Medical University trials in China

Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors Recruiting

Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors Recruiting

Self-Management Support for Acute Coronary Syndrome Patients After Hospital Discharge Starting soon

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Recruiting

Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas Recruiting

Other trials for the same condition

Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia Starting soon

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML Active, not recruiting

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML Recruiting

Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity Recruiting

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05875649 on ClinicalTrials.gov ↗ ← All trials in China